From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Immupharma: “Breakthrough Findings into Autoimmune Diseases” – ‘an undertaking of great advantage, but nobody to know what it is’!?

By Steve Moore | Thursday 9 January 2025


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Immupharma (IMM) has issued a “Breakthrough Findings into Autoimmune Diseases”-titled announcement and the shares have currently responded more than 180% higher to 3.4p and a £14.2 million market cap. So what are the “breakthrough findings” and of what direct financial import are they to the company?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Monday »

ICON

Iconic Labs, the world has gone mad!

Time left: 22:22:10